Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSP Inspire Medical Systems	$156.54 +3.5%	$157.31	$123.00 ▼ $225.00	$4.62B	1.39	563,622 shs	376,686 shs
NVCR NovoCure	$18.57 +6.8%	$17.90	$14.17 ▼ $34.13	$2.07B	0.73	1.17 million shs	1.05 million shs
STVN Stevanato Group	€23.64 -1.5%	€21.22	€16.56 ▼ €24.90	$7.16B	0.51	350,713 shs	322,500 shs
SWAV Shockwave Medical	$334.75	$332.85	$157.00 ▼ $334.90	$12.57B	0.88	968,088 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSP Inspire Medical Systems	+3.27%	-1.96%	+6.42%	-14.54%	-6.73%
NVCR NovoCure	+6.85%	+4.56%	+12.55%	-12.45%	+12.75%
STVN Stevanato Group	-1.17%	+6.92%	+8.29%	+17.61%	+8.34%
SWAV Shockwave Medical	0.00%	0.00%	0.00%	0.00%	+1.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSP Inspire Medical Systems	4.8805 of 5 stars	4.4	3.0	0.0	4.8	2.8	2.5	1.9
NVCR NovoCure	4.0329 of 5 stars	3.3	3.0	0.0	4.5	3.5	1.7	0.0
STVN Stevanato Group	1.0282 of 5 stars	0.0	1.0	1.7	0.0	2.7	0.0	1.9
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSP Inspire Medical Systems	2.73	Moderate Buy	$211.91	35.37% Upside
NVCR NovoCure	2.67	Moderate Buy	$32.83	76.81% Upside
STVN Stevanato Group	2.86	Moderate Buy	N/A	N/A
SWAV Shockwave Medical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NVCR, STVN, INSP, and SWAV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/6/2025	INSP Inspire Medical Systems	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$220.00 ➝ $200.00
5/6/2025	INSP Inspire Medical Systems	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$235.00 ➝ $195.00
5/6/2025	INSP Inspire Medical Systems	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$195.00 ➝ $174.00
5/6/2025	INSP Inspire Medical Systems	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$230.00 ➝ $236.00
4/23/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$42.00 ➝ $34.00
4/21/2025	INSP Inspire Medical Systems	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$190.00 ➝ $175.00
4/21/2025	INSP Inspire Medical Systems	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$234.00 ➝ $216.00
4/21/2025	STVN Stevanato Group	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/16/2025	NVCR NovoCure	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $27.00
4/15/2025	INSP Inspire Medical Systems	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$260.00 ➝ $215.00
4/10/2025	NVCR NovoCure	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $28.00

(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSP Inspire Medical Systems	$840.11M	5.50	$1.50 per share	104.41	$23.25 per share	6.73
NVCR NovoCure	$621.71M	3.33	N/A	N/A	$3.39 per share	5.48
STVN Stevanato Group	$1.10B	6.48	€0.99 per share	23.97	€4.15 per share	5.70
SWAV Shockwave Medical	$787.97M	15.95	$4.31 per share	77.61	$20.02 per share	16.72

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSP Inspire Medical Systems	$53.51M	$2.17	90.49	48.61	2.86	6.67%	8.19%	7.09%	N/A
NVCR NovoCure	-$207.04M	-$1.51	N/A	N/A	N/A	-25.93%	-41.48%	-12.74%	7/24/2025 (Estimated)
STVN Stevanato Group	$157.62M	€0.51	50.30	40.76	7.18	10.47%	9.86%	5.79%	N/A
SWAV Shockwave Medical	$147.28M	$4.28	78.21	54.34	2.43	20.75%	24.79%	11.95%	N/A

Latest NVCR, STVN, INSP, and SWAV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	INSP Inspire Medical Systems	-$0.23	$0.10	+$0.33	$0.10	$194.89 million	$201.32 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million
3/6/2025	Q4 2024	STVN Stevanato Group	€0.20	€0.20	N/A	€0.19	€346.26 million	€352.68 million
2/27/2025	Q4 2024	NVCR NovoCure	-$0.34	-$0.61	-$0.27	-$0.61	$161.30 million	$161.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSP Inspire Medical Systems	N/A	N/A	N/A	N/A	N/A
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
STVN Stevanato Group	€0.06	0.25%	N/A	11.76%	1 Years
SWAV Shockwave Medical	N/A	N/A	N/A	N/A	N/A

Latest NVCR, STVN, INSP, and SWAV Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	STVN Stevanato Group	annual	€0.06	0.3%	6/5/2025	6/5/2025	7/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSP Inspire Medical Systems	N/A	7.13	6.22
NVCR NovoCure	0.27	1.49	1.44
STVN Stevanato Group	0.22	1.81	1.21
SWAV Shockwave Medical	0.97	13.81	12.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSP Inspire Medical Systems	94.91%
NVCR NovoCure	84.61%
STVN Stevanato Group	N/A
SWAV Shockwave Medical	95.35%

Insider Ownership

Company	Insider Ownership
INSP Inspire Medical Systems	4.10%
NVCR NovoCure	6.29%
STVN Stevanato Group	0.70%
SWAV Shockwave Medical	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSP Inspire Medical Systems	760	29.49 million	28.45 million	Optionable
NVCR NovoCure	1,320	111.49 million	101.40 million	Optionable
STVN Stevanato Group	4,650	302.84 million	300.72 million	Optionable
SWAV Shockwave Medical	1,468	37.54 million	36.27 million	Optionable

NVCR, STVN, INSP, and SWAV Headlines

Recent News About These Companies

Shockwave Medical unveil Forward Intravascular Lithotripsy Platform in US

March 6, 2025 | medicaldialogues.in

Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions

March 4, 2025 | finance.yahoo.com

Shockwave Medical’s Javelin IVL catheter meets primary trial endpoints

November 5, 2024 | massdevice.com

Shockwave Medical concludes enrollment in all-female coronary IVL study

November 2, 2024 | medicaldialogues.in

Shockwave completes enrollment in all-female cardiovascular trial

October 30, 2024 | bioworld.com

Shockwave Medical completes enrollment in all-female IVL study

October 29, 2024 | massdevice.com

Micro-shockwave electronic therapy shows potential for safe non-invasive treatment of brain disorders

October 28, 2024 | medicalxpress.com

Mayo Clinic Q&A: Shockwave therapy may help relieve foot problem

October 27, 2024 | postbulletin.com

Johnson & Johnson completes $1.7B V-Wave acquisition

October 9, 2024 | massdevice.com

New shockwave therapy offers hope for chronic pain sufferers

September 25, 2024 | local12.com

Shockwave E8: Extend Your Capabilities With the New Peripheral IVL Workhorse

September 24, 2024 | evtoday.com

Shockwave E8 Peripheral IVL Catheter Launched

September 17, 2024 | evtoday.com

Smiths Medical recalls airway tubes over defect linked to more than 10 injuries

September 17, 2024 | medtechdive.com

J&J’s Shockwave adds enhanced catheter to U.S. IVL portfolio

September 17, 2024 | massdevice.com

J&J’s Shockwave strengths IVL grasp with new US catheter launch

September 17, 2024 | msn.com

New noninvasive technique provides effective treatment for urinary stones

September 12, 2024 | msn.com

Balancing Growth and Challenges: A Hold Rating for Johnson & Johnson’s Medtech Division Amidst China Headwinds

September 6, 2024 | markets.businessinsider.com

September 2024 edition: The Medtech Big 100, PFA catheters and Shockwave’s Reducer

August 30, 2024 | medicaldesignandoutsourcing.com

Baird Q2 2024 Small/Mid Cap Growth Equity Fund Commentary

August 22, 2024 | seekingalpha.com

Introducing OMNIWave(TM): Revolutionizing Treatment with Advanced Shockwave Technology and Comprehensive Business Solutions

August 15, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
These 3 Rock Star Entertainment Stocks Are Dominating 2025
By Leo Miller | May 7, 2025
View These 3 Rock Star Entertainment Stocks Are Dominating 2025
Survey: America’s Most Inspirational Women Business Leaders [2025]
By MarketBeat Staff | May 7, 2025
View Survey: America’s Most Inspirational Women Business Leaders [2025]
The Most Inspiring Small Businesses of 2025 [Survey]
By MarketBeat Staff | May 1, 2025
View The Most Inspiring Small Businesses of 2025 [Survey]

NVCR, STVN, INSP, and SWAV Company Descriptions

Inspire Medical Systems NYSE:INSP

$156.54 +5.29 (+3.50%)

Closing price 05/12/2025 03:59 PM Eastern

Extended Trading

$156.51 -0.03 (-0.02%)

As of 04:56 AM Eastern

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

NovoCure NASDAQ:NVCR

$18.57 +1.19 (+6.85%)

Closing price 05/12/2025 04:00 PM Eastern

Extended Trading

$17.58 -0.98 (-5.30%)

As of 04:52 AM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stevanato Group NYSE:STVN

€23.64 -0.36 (-1.50%)

As of 05/12/2025 03:52 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Shockwave Medical NASDAQ:SWAV

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time